European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 141, Issue 2 , Pages 163-168 , December 2008

The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinoma

  • Emma C. Batchelor

      Affiliations

    • Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 843 412 4843; fax: +1 843 792 5498.
    • ,
  • John M. Watkins

      Affiliations

    • Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA
    • ,
  • William T. Creasman

      Affiliations

    • Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC, USA
    • ,
  • Matthew F. Kohler

      Affiliations

    • Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC, USA
    • ,
  • Debajyoti Sinha

      Affiliations

    • Department of Biostatistics, Bioinformatics, and Epidemiology, Medical University of South Carolina, Charleston, SC, USA
    • ,
  • Joseph M. Jenrette

      Affiliations

    • Department of Radiation Oncology, Medical University of South Carolina, Charleston, SC 29425, USA

Received 19 February 2008 ,Revised 19 June 2008 ,Accepted 7 July 2008.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2007;57:43–66
  2. Wilson TO, Podratz KC, Gaffey TA, et al. Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma. Am J Obstet Gynecol. 1990;162:418–423
  3. Faratian D, Stillie A, Busby-Earle RM, et al. A review of the pathology and management of uterine papillary serous carcinoma and correlation with outcome. Int J Gynecol Cancer. 2006;16:972–978
  4. Mehta N, Yamada SD, Rotmensch J, et al. Outcome and pattern of failure in pathologic stage I–II papillary serous carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003;57:1004–1009
  5. Murphy KT, Rotmensch J, Yamada SD, et al. Outcome and patterns of failure in pathologic stages I–IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys. 2003;55:1272–1276
  6. Rosenberg P, Blom R, Hogberg T, et al. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol. 1993;51:311–315
  7. Christopherson WM, Alberhaskey RC, Connely PJ. Carcinoma of the endometrium: I. a clinicopathologic study of clear cell carcinoma and secretory carcinoma. Cancer. 1982;49:1511–1514
  8. Albeler VM, Kjorstad KE. Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol. 1991;40:207–217
  9. Carcangiu ML, Chambers JT. Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival. Int J Gynecol Pathol. 1995;14:30–38
  10. Abeler VM, Vergote IB, Kjorstad KE, et al. Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer. 1996;78:1740–1747
  11. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40:55–65
  12. Sall S, Sonnenblick B, Stone ML. Factors affecting survival of patients with endometrial adenocarcinoma. Am J Obstet Gynecol. 1970;107:116–123
  13. NCCN.org. 1 May 2008. NCCN Practice Guidelines in Oncology; 14 April 2008. <http://www.nccn.org/professionals/physician_gls/PDF/uterine.pdf>.
  14. Lim P, Al Kushi A, Gilks B, et al. Early stage uterine papillary serous carcinoma of the endometrium: effect of adjuvant whole abdominal radiotherapy and pathologic parameters on outcome. Cancer. 2001;91:752–757
  15. Piura B, Meirovitz M, Shulman M, et al. Uterine papillary serous carcinoma: study of 19 cases. Eur J Obstet Gynecol Reprod Bio. 1998;79:69–73
  16. Cirisano FD, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol. 2000;77:55–65
  17. Tay EH, Ward BG. The treatment of uterine papillary serous carcinoma: are we doing the right thing?. Int J Gynecol Cancer. 1999;9:463–469
  18. Bristow RE, Asrari F, Trimble EL, et al. Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (stage I–II) disease. Gynecol Oncol. 2001;81:279–286
  19. Turner BC, Knisely JP, Kacinski BM, et al. Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy. Int J Radiat Oncol Biol Phys. 1998;40:77–84
  20. Grice J, Ek M, Greer B, et al. Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients. Gynecol Oncol. 1998;69:69–73
  21. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol. 1992;47:298–305
  22. Nguyen NP, Sallah S, Karlsson U, et al. Prognosis for papillary serous carcinoma of the endometrium after surgical staging. Int J Gynecol Cancer. 2001;11:305–311
  23. Gehrig PA, Groben PA, Fowler WC, et al. Noninvasive papillary serous carcinoma of the endometrium. Obstet Gynecol. 2001;97:153–157
  24. Kelly M, O’Mally DM, Hui P. Improved survival in surgical stage I patients with uterine papillary serous carcinomas (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol. 2005;98:353–359
  25. Rosenberg P, Boeryd B, Simonsen E. A new aggressive treatment approach to high-grade endometrial cancer of possible benefit to patients with stage I uterine papillary cancer. Gynecol Oncol. 1993;48:32–37
  26. Hamilton CA, Kapp DS, Chan JK. Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol. 2008;20:26–33
  27. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24:36–44
  28. Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus figrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:2159–2166
  29. Hamilton CA, Cheung MK, Osann K, et al. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol. 2006;103:679–683
  30. Vaidya AP, Littell R, Krasner C, Duska LR. Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J of Gynecol Cancer. 2006;16:267–272

PII: S0301-2115(08)00293-5

doi: 10.1016/j.ejogrb.2008.07.019

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 141, Issue 2 , Pages 163-168 , December 2008

Article Tools

* Image Usage & Resolution